Near-Fatal Asthma Treated with Omalizumab

Background: Near-fatal asthma treated with Omalizumab The near-fatal asthma is a severe form of asthma that threatens the life of patients and is associated with poorly controlled chronic asthma, accounting for limitations in the quality of life. Presents with ongoing chronic inflammation and irreversible changes in the airway. Treatment is difficult, however with the use of omalizumab can decrease the risk of mortality in these patients. Objective is Evaluating clinical improvement, spirometric and income to the emergency hospitalization and intensive care unit, as well as near-fatal asthma episodes in patients with uncontrolled asthma in treatment with con Omalizumab Methods: We evaluated 4 patients with poorly controlled asthma and near-fatal episodes of asthma who were administered doses of omalizumab and IgE established according to weight, evaluating clinical, spirometric well as income to the emergency room and hospital intensive care unit . Results: There was a significant clinical improvement in 4 patients after treatment with omalizumab with improved daytime symptoms by 75% and 68% nocturnal p ≤ 0.001, as well as 100% improvement in revenue and hospitalizations to floor, well as income to the ICU with P ≤ 0.001. No further episodes of near-fatal asthma. In addition to decreased use of systemic steroids 90% (p0.003) and inhaled steroids 60% (p0.005) Conclusions: Omalizumab is a good treatment option in patients with poorly controlled asthma with near-fatal asthma episodes